Marc Lajoie
Marc Lajoie is Co-founder and Chief Executive Officer at Outpace Bio. He was Co-founder and Senior Director of Protein & Cell Engineering at Lyell Immunopharma and Co-founder and Advisor at GRO Biosciences. He was a Washington Research Foundation Innovation Postdoctoral Fellow and Cancer Research Institute Fellow at the University of Washington.
Seattle's Dexter Yard Develops into Major South Lake Union Biotech Cluster with Outpace Bio and Allen Institute
Seattle's Dexter Yard has become a growing biotech and life sciences hub, attracting companies like Outpace Bio and the Allen Institute with 528,000 square feet of new lab and office space. The area, located in South Lake Union, is part of a larger regional expansion of science facilities supported by major real estate developments and significant biotech investment.
Outpace Bio raises $30M Series A to develop custom T cell therapies, partners with Lyell Immunopharma
Seattle startup Outpace Bio raised $30 million in a Series A to develop software and hardware for designing custom cell- and gene-based therapies, initially targeting T cell treatments for solid tumors. The 18-person company, led by co-founder and CEO Marc Lajoie, also announced a partnership with Lyell Immunopharma and counts ARTIS Ventures and Lyell among its investors.
Organizations
See all 5-
Outpace Bio Executive Officer, Director, Promoter 2024–present, Co-founder & Chief Executive Officer 2020–present · current
-
Lyell Immunopharma Co-founder, Sr. Director - Protein & Cell Engineering 2019–2020 · past
-
GRO Biosciences Co-founder, Advisor 2016–2025 · past
Education
-
Harvard University Ph.D, Chemical Biology Program · 2008–2013
-
Dartmouth College BA, Biophysical Chemistry · 2004–2008